Drug intelligence / Profile preview

burapitant

Development stage: Phase 2
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

Burapitant (SSR240600C) is a small molecule drug developed by Sanofi that acts as a potent and selective antagonist of the neurokinin 1 receptor (NK1R). It was investigated primarily for the treatment of overactive bladder and urge urinary incontinence. The mechanism of action involves blocking NK1 receptors, which are implicated in the regulation of bladder function and other urogenital processes. Clinical trials reached Phase 2 for these indications but did not progress to approval or further development[5][7].

Other names: burapitant

Targets

TACR1 (Neurokinin‑1 Receptor)

Beyond the preview

Go deeper on burapitant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on burapitant.

Explore the full profile